Cheng Yuan

Dr. Cheng Yuan


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
CYCheng Yuan
Cheng Yuan
DCDeng-Jing Chen
Deng-Jing Chen
QYQiu-Xiang Ye
Qiu-Xiang Ye
KXKai Xiao
Kai Xiao
LHLi-Sheng Hao
Li-Sheng Hao
YNYan-Qing Nan
Yan-Qing Nan

21 February 2024 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
YYYing Yu
Ying Yu
LWLi Yun Wang
Li Yun Wang
YLYan Chi Liu
Yan Chi Liu
HCHao Cui
Hao Cui
CYCheng Yuan
Cheng Yuan
CWChengxiao Wang
Chengxiao Wang

24 May 2024 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
LHLi-Sheng Hao
Li-Sheng Hao
YMYa-Qi Meng
Ya-Qi Meng
YWYan-Si Wang
Yan-Si Wang
YNYan-Qing Nan
Yan-Qing Nan
CYCheng Yuan
Cheng Yuan
HWHan-Xiao Wang
Han-Xiao Wang

21 October 2025 in Colloids and Surfaces A: Physicochemical and Engineering Aspects
Verified
Journal Article
Closed access
YNYan-Qing Nan
Yan-Qing Nan
SWSheng Wang
Sheng Wang
CYCheng Yuan
Cheng Yuan

27 July 2026 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
LWLei Wang
Lei Wang
WDWeifeng Dai
Weifeng Dai
CYCheng Yuan
Cheng Yuan
YQYi Qin
Yi Qin
YCYonggang Chen
Yonggang Chen
MZMi Zhang
Mi Zhang
Introduction: Fulvic acid (FA) is a mineral-based traditional Chinese medicine, which is commonly used to treat gastrointestinal diseases. The aim of this study is to investigate the protective effects of FA against 5-FU-induced intestinal injury in vivo and elucidate its potential mechanisms. Methods: Mice are randomly divided into 8 groups, including a control group, a model group, PPI treated group (omeprazolea, positive drug), LPDA treated group (loperamidean, positive drug), and four doses (25 mg/kg, 50 mg/kg, 100 mg/kg, 150 mg/kg) of FA treated groups (FA-25, FA- 50, FA-100, FA-150). Histopathological examinations were carried out to assess the protective impact of FA. Transcriptome sequencing, qPCR (quantitative PCR), and western blot analyses were conducted to explore the mechanism of FA. Results: Intragastric administration of 5 g/kg FA did not cause acute toxicity in mice. Histopathological examination of the mouse small intestine showed that FA-treated groups had improved morphology. Transcriptome sequencing revealed 69 DEGs that were significantly different between the FA-treated group and the model group. KEGG pathway analysis revealed that these genes were predominantly associated with the cytokine–cytokine receptor interaction pathway. qPCR validation confirmed the expression profiles of crucial differentially expressed genes, specifically Csf3r, Csf2rb, and Csf2rb2. Western blot analysis confirmed the Csf3r and Csf2rb protein expression results. Discussion: This study suggests that FA protects against 5-FU-induced intestinal injury and is associated with upregulation of granulocyte-related gene expression. Conclusion: These observations suggest that FA has a protective effect against 5-FU-induced intestinal injury. However, these findings are still preclinical, and their therapeutic potential remains to be further validated in large-animal models and human cell-based systems.

24 January 2023 in Zeitschrift für Kristallographie - New Crystal Structures
Verified
Journal Article
Open access
PDF file
SSShixiong Sun
Shixiong Sun
BZBenbo Zhao
Benbo Zhao
PDPing Deng
Ping Deng
CYCheng Yuan
Cheng Yuan
C15H14O3, M = 242.26 g/mol, monoclinic, P21/c (no. 14), a = 5.5859(10) Å, b = 24.818(4) Å, c = 9.3393(15) Å, β = 101.128(3)°, V = 1270.4(4) Å3, Z = 4, R gt (F) = 0.0410, wR ref (F 2) = 0.1394, T = 296(2) K.